Bio News
Daewoong Pharmaceutical has launched Fexuclue 40 mg, a treatment for gastroesophageal reflux disease, in Indonesia.
Fexuclue was approved locally for the treatment of erosive gastroesophageal reflux disease.
Daewoong Pharmaceutical plans to conduct a multinational phase 3 trial in South Korea and Indonesia to expand the indication to gastric ulcers.
Biobook Team
biobookmedia@biobook.co.krParagon Spin-Off Velaris Goes Public Through Reverse Merger With Alaunos
Syndax halts development of Niktimvo for pulmonary fibrosis; shares plunge 17%
BioNTech’s mRNA Cancer Vaccine Misses Primary Endpoint for Progression-Free Survival in Phase 3 Trial
Roche Signs $1.6 Billion Deal With China’s Rona for ALK7 Obesity Drug
Formycon and Zydus’ Keytruda Biosimilar Is First to Be Accepted for FDA Review
Pfizer Signs $500 Million Protein Degrader Deal With Enodia
